Neuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025

Reuters

2025/12/02

Neuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025

NeuroPace Inc. has announced that new clinical data and advances related to its RNS System and AI-powered NeuroPace platform will be featured at the 2025 American Epilepsy Society $(AES)$ Annual Meeting in Atlanta, Georgia. The company will present new analyses from the RNS System Post-Approval Study (PAS), including long-term seizure reduction durability and quality-of-life outcomes in drug-resistant focal epilepsy populations. Preliminary 18-month safety and efficacy results from the NAUTILUS clinical trial, which evaluates responsive thalamic stimulation for idiopathic generalized epilepsy, will also be presented. In addition, NeuroPace will provide an initial overview of its next-generation AI and SeizureID tools, designed to enhance epilepsy care through advanced analysis of intracranial EEG data. These results and tools are scheduled to be presented at the upcoming AES 2025 meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202649264) on December 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2588053402"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588053402\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588053402?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588053402","market":"us","top_or_hot":-1,"title":"Neuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Neuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NPCE\">NeuroPace Inc.</a> has announced that new clinical data and advances related to its RNS System and AI-powered NeuroPace platform will be featured at the 2025 American Epilepsy Society <a href=\"https://laohu8.com/S/AES\">$(AES)$</a> Annual Meeting in Atlanta, Georgia. The company will present new analyses from the RNS System Post-Approval Study (PAS), including long-term seizure reduction durability and quality-of-life outcomes in drug-resistant focal epilepsy populations. Preliminary 18-month safety and efficacy results from the NAUTILUS clinical trial, which evaluates responsive thalamic stimulation for idiopathic generalized epilepsy, will also be presented. In addition, NeuroPace will provide an initial overview of its next-generation AI and SeizureID tools, designed to enhance epilepsy care through advanced analysis of intracranial EEG data. These results and tools are scheduled to be presented at the upcoming AES 2025 meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202649264) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Neuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NPCE\">NeuroPace Inc.</a> has announced that new clinical data and advances related to its RNS System and AI-powered NeuroPace platform will be featured at the 2025 American Epilepsy Society <a href=\"https://laohu8.com/S/AES\">$(AES)$</a> Annual Meeting in Atlanta, Georgia. The company will present new analyses from the RNS System Post-Approval Study (PAS), including long-term seizure reduction durability and quality-of-life outcomes in drug-resistant focal epilepsy populations. Preliminary 18-month safety and efficacy results from the NAUTILUS clinical trial, which evaluates responsive thalamic stimulation for idiopathic generalized epilepsy, will also be presented. In addition, NeuroPace will provide an initial overview of its next-generation AI and SeizureID tools, designed to enhance epilepsy care through advanced analysis of intracranial EEG data. These results and tools are scheduled to be presented at the upcoming AES 2025 meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202649264) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL2z9Zcz:1","article_id":"2588053402","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588053402","pubTimestamp":1764680520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeuroPace Inc. has announced that new clinical data and advances related to its RNS System and AI-powered NeuroPace platform will be featured at the 2025 American Epilepsy Society  Annual Meeting in Atlanta, Georgia. The company will present new analyses from the RNS System Post-Approval Study , including long-term seizure reduction durability and quality-of-life outcomes in drug-resistant focal epilepsy populations. Preliminary 18-month safety and efficacy results from the NAUTILUS clinical trial, which evaluates responsive thalamic stimulation for idiopathic generalized epilepsy, will also be presented. In addition, NeuroPace will provide an initial overview of its next-generation AI and SeizureID tools, designed to enhance epilepsy care through advanced analysis of intracranial EEG data. These results and tools are scheduled to be presented at the upcoming AES 2025 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4082":"医疗保健设备","NPCE":"NeuroPace Inc."},"translate_title":"Neuropace在AES 2025上推出用于RNS系统的新临床数据和人工智能工具","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NPCE":0.9},"content_text":"Neuropace Unveils New Clinical Data and AI Tools for RNS System at AES 2025\n    \n\nNeuroPace Inc. has announced that new clinical data and advances related to its RNS System and AI-powered NeuroPace platform will be featured at the 2025 American Epilepsy Society $(AES)$ Annual Meeting in Atlanta, Georgia. The company will present new analyses from the RNS System Post-Approval Study (PAS), including long-term seizure reduction durability and quality-of-life outcomes in drug-resistant focal epilepsy populations. Preliminary 18-month safety and efficacy results from the NAUTILUS clinical trial, which evaluates responsive thalamic stimulation for idiopathic generalized epilepsy, will also be presented. In addition, NeuroPace will provide an initial overview of its next-generation AI and SeizureID tools, designed to enhance epilepsy care through advanced analysis of intracranial EEG data. These results and tools are scheduled to be presented at the upcoming AES 2025 meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202649264) on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}